Carregant...
ESR1 Mutations in Breast Cancer
The acquisition of ligand-independent ESR1 mutations during aromatase inhibitor (AI) therapy in metastatic estrogen receptor (ER)-positive breast cancer is a common mechanism of hormonal therapy resistance. Preclinical and clinical studies have demonstrated that ESR1 mutations can pre-exist in prima...
Guardat en:
| Publicat a: | Cancer |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6788940/ https://ncbi.nlm.nih.gov/pubmed/31318440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32345 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|